1.2364

3.41% -0.0437

After Hours: 1.24 0.0036 +0.29%

Plus Therapeutics Inc (PSTV)

Overview News Price History Financials Discussions Forecast Stock Split

Plus Therapeutics Inc stock is traded at $1.2364, with a volume of 16,094. It is down -3.41% in the last 24 hours and down -0.29% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Previous Close:

$1.2801

Open:

$1.25

24h Volume:

16,094

Relative Volume:

0.22

Market Cap:

$7.31M

Revenue:

Net Income/Loss:

$-12.89M

P/E Ratio:

-0.4887

EPS:

-2.53

Net Cash Flow:

$-11.95M

1W Performance:

-0.29%

1M Performance:

-0.29%

6M Performance:

-21.25%

1Y Performance:

-36.27%

1-Day Range:

$1.22

$1.28

1-Week Range:

$1.175

$1.32

52-Week Range:

$0.925

$2.6702

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name

Plus Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

737.255.7194

Address

4200 MARATHON BLVD., AUSTIN, TX

Employee

Twitter

@plustxinc

Next Earnings Date

2024-11-04

Latest SEC Filings

PSTV's Discussions on Twitter

Compare PSTV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PSTV Plus Therapeutics Inc	1.2364	7.31M	0	-12.89M	-11.95M	-2.53
VRTX Vertex Pharmaceuticals Inc	469.23	122.13B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	710.00	78.30B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	646.64	39.73B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.19	35.50B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.61	28.47B	3.30B	-501.07M	1.03B	-2.1146

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy
Oct-16-20	Initiated	Maxim Group	Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

Feb 05, 2025

Glioma Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight - EIN News

Feb 05, 2025

Jan 23, 2025

MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire

Jan 23, 2025

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - Yahoo Finance UK

Jan 23, 2025

Jan 15, 2025

Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR

Jan 15, 2025

Jan 14, 2025

Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail

Jan 14, 2025

Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR

Jan 14, 2025

Jan 13, 2025

Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal - STAT

Jan 13, 2025

Jan 08, 2025

Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR

Jan 08, 2025

Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World

Jan 08, 2025

Jan 07, 2025

Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra

Jan 07, 2025

Dec 27, 2024

Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha

Dec 27, 2024

Dec 26, 2024

Sermonix and Henlius Dose First Chinese Patient in Phase 3 - GlobeNewswire

Dec 26, 2024

Dec 24, 2024

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace

Dec 24, 2024

Dec 17, 2024

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire

Dec 17, 2024

Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan

Dec 17, 2024

Dec 16, 2024

PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK

Dec 16, 2024

Dec 12, 2024

Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT

Dec 12, 2024

Dec 11, 2024

Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance

Dec 11, 2024

Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire

Dec 11, 2024

Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics - STAT

Dec 11, 2024

Dec 10, 2024

Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World

Dec 10, 2024

Dec 09, 2024

Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times

Dec 09, 2024

National Resilience’s new CEO; Moderna opens Australian manufacturing site - Endpoints News

Dec 09, 2024

Dec 04, 2024

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire

Dec 04, 2024

Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan

Dec 04, 2024

Dec 03, 2024

Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire

Dec 03, 2024

Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan

Dec 03, 2024

Key Drivers of AI Drug Discovery - Genetic Engineering & Biotechnology News

Dec 03, 2024

Nov 30, 2024

HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World

Nov 30, 2024

Nov 26, 2024

Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com

Nov 26, 2024

Nov 25, 2024

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network

Nov 25, 2024

Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan

Nov 22, 2024

PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK

Nov 22, 2024

Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire

Nov 22, 2024

Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire

Nov 21, 2024

Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan

Nov 21, 2024

Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT

Nov 21, 2024

Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024

Nov 18, 2024

Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com

Nov 18, 2024

Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com

Nov 18, 2024

Nov 17, 2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Plus: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024